How Longenesis helps achieve more affordable and improved healthcare delivery
Longenesis is a partnership between Insilico Medicine, a leading artificial intelligence company that uses deep learning for drug discovery, and the Bitfury Group, the leading full-service blockchain technology company. Longenesis is the exclusive healthcare application provider for open-source framework Exonum™.
Longenesis has developed a blockchain solution that uses AI-integrated toolsets to store, manage, analyze, and exchange healthcare-related data such as lab test results. The main goal of the company is to accelerate the development of healthcare by providing the solutions (for pharma, clinics, researchers, data analytics companies, and patients) for data management and data analytics utilizing blockchain and AI technologies.
The Longenesis health data management solution enables hospitals to upload, store, and manage the data of individual patients in a secure environment, giving full control of data usage and access back to patients. Hospitals can also better handle consent forms and status for individual researchers, which better facilitate the advancement of clinical trials.
Longenesis is a powerful solution for medical providers, supplying everything from user interfaces for patient interaction to medical recordkeeping. But its main focus has become medical-consent technologies. It streamlines data collection and aggregation, improves medical research processes, and enables transparent patient consent management. This is important as medical data access and security are more carefully regulated worldwide, necessitating technological advances. Thus Longenesis works in compliance with the Health Insurance Portability and Accountability Act (HIPAA) and General Data Protection Regulation (GDPR). Hence, it meets both US and EU standards.
With its platform, researchers get a fuller picture of patients, and every step of the process is linked, verifiable and auditable. The patient agrees to specified care or participation in a study or a trial. Patients can withdraw that agreement, while the medical provider can offer to extend, modify, or amend the agreement.
Longenesis Themis is a dynamic consent management toolkit solving the legal challenge of legitimate biomedical data utilization for clinical studies, allowing patients to be proactively involved in the clinical and research projects and providing transparency and auditability mechanisms, putting patients as a centric stakeholder of such process.
Longenesis Proteus allows any clinical and research institution, patients association, biobank, and MedTech company to join the network and get connected with Clinical Research organizations and Pharma companies for proactive patient involvement.
Longenesis has also conducted studies on Breast Cancer multi-modal risk calculation, Diabetes patients’ medical treatment monitoring and pharmacovigilance, being well-equipped to address patient needs in the APAC region.
More Affordable and Improved Healthcare
Longenesis will be providing its medical-consent platform-as-a-service to hospitals and labs. The system works with pharmaceutical companies and research institutions who can peruse the anonymous metadata to see what information might be available. They can then offer the owner of the data, the patient, the opportunity to participate in trials or studies or release their existing information for use in the evaluation of medicines or procedures. Longenesis offers a transparent chain from the patient through to the hospital making more information available to the researchers, who now face problems of quantity and quality of relevant data.
Making data available for healthcare innovations like drug discovery and development contributes in many ways to making healthcare more affordable and improving the quality of healthcare available. In a special way it helps in the development of more personalized and potent healthcare products and services.
Longenesis Media contact:
info@longenesis.com
+37126354885
This story was originally published on MedNeed.com
